Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α, and TNF-related apoptosis-inducing ligand in prostate cancer

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4537-4545

  An, Jiabin ^a   Sun, Yi Ping ^a   Adams, Julian ^b   Fisher, Myrna ^a   Belldegrun, Arie ^c   Rettig, Matthew B ^a,c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; REPORTER GENE;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BORONIC ACIDS; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; DRUG INTERACTIONS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; LUCIFERASES; MALE; MEMBRANE GLYCOPROTEINS; MULTIENZYME COMPLEXES; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141925950     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Sudakin, V., Ganoth, D., Dahan, A., Heller, H., Hershko, J., Luca, F. C., Ruderman, J. V., and Hershko, A. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol. Biol. Cell, 6: 185-197, 1995.
2. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Wash. DC), 269: 682-685, 1995.
3. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NFκ-B1 precursor protein and the activation of NF-κB. Cell, 78: 773-785, 1994.
4. Maki, C. G., Huibregtse, J. M., and Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res., 56: 2649-2654, 1996.
5. Treier, M., Staszewski, L. M., and Bohmann, D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell, 78: 787-798, 1994.
6. Ciechanover, A., and Schwartz, A. L. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc. Natl. Acad. Sci. USA, 95: 2727-2730, 1998.
7. Frankel, A., Man, S., Elliott, P., Adams, J., and Kerbel, R. S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res., 6: 3719-3728, 2000.
8. Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 59: 2615-2622, 1999.
9. Sutherland, R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (Wash. DC), 240: 177-184, 1988.
10. Olive, P. L., and Durand, R. E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastisis Rev., 13: 121-138, 1994.
11. Herrmann, J. L., Briones, F., Jr., Brisbay, S., Logothetis, C. J., and McDonnell, T. J. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 17: 2889-2899, 1998.
12. Cusack, J. C., Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P. J., Adams, J., and Baldwin, A. S., Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res., 61: 3535-3540, 2001.
13. Yu, R., Mandlekar, S., Ruben, S., Ni, J., and Kong, A. N. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res., 60: 2384-2389, 2000.
14. Nimmanapalli, R., Perkins, C. L., Orlando, M., O'Bryan, E., Nguyen, D., and Bhalla, K. N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res., 61: 759-763, 2001.
15. Nesterov, A., Lu, X., Johnson, M., Miller, G. J., Ivashchenko, Y., and Kraft, A. S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem., 276: 10767-10774, 2001.
16. Muenchen, H. J., Lin, D. L., Walsh, M. A., Keller, E. T., and Pienta, K. J. Tumor necrosis factor-α-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-κB by an IκBα "super-repressor". Clin. Cancer Res., 6: 1969-1977, 2000.
17. Nakajima, Y., DelliPizzi, A. M., Mallouh, C., and Ferreri, N. R. TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines. Prostate, 29: 296-302, 1996.
18. Palayoor, S. T., Youmell, M. Y., Calderwood, S. K., Coleman, C. N., and Price, B. D. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene, 18: 7389-7394, 1999.
19. Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D., and Fidler, I. J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 20: 4188-4197, 2001.
20. Chen, C. D., and Sawyers, C. L. NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell. Biol., 22: 2862-2870, 2002.
21. Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res., 60: 2323-2330, 2000.
22. Das, K. C., and White, C. W. Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem., 272: 14914-14920, 1997.
23. Patel, B. J., Pantuck, A. J., Zisman, A., Tsui, K. H., Paik, S. H., Caliliw, R., Sheriff, S., Wu, L., deKernion, J. B., Tso, C. L., and Belldegrun, A. S. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J. Urol., 164: 1420-1425, 2000.
24. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
25. Kimura, K., Markowski, M., Bowen, C., and Gelmann, E. P. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res., 61: 5611-5618, 2001.
26. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., and Smith, C. A. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3: 673-682, 1995.
27. Marsters, S. A., Pitti, R. M., Donahue, C. J., Ruppert, S., Bauer, K. D., and Ashkenazi, A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol., 6: 750-752, 1996.
28. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271: 12687-12690, 1996.
29. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Wash. DC), 274: 784-787, 1996.
30. Adams, J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol., 6: 493-500, 2002.
31. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., and Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 61: 3071-3076, 2001.
32. Herrmann, J. L., Briones, F., Jr., Brisbay, S., Logothetis, C. J., and McDonnell, T. J. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 17: 2889-2899, 1998.
33. Gasparian, A. V., Yao, Y. J., Kowalczyk, D., Lyakh, L. A., Karseladze, A., Slaga, T. J., and Budunova, I. V. The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cells. J. Cell Sci., 115: 141-151, 2002.
34. Suh, J., Payvandi, F., Edelstein, L. C., Amenta, P. S., Zong, W. X., Gelinas, C., and Rabson, A. B. Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate, 52: 183-200, 2002.
35. Munshi, A., Pappas, G., Honda, T., McDonnell, T. J., Younes, A., Li, Y., and Meyn, R. E. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene, 20: 3757-3765, 2001.
36. Zisman, A., Ng, C. P., Pantuck, A. J., Bonavida, B., and Belldegrun, A. S. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J. Immunother., 24: 459-471, 2001.
37. Eid, M. A., Lewis, R. W., Abdel-Mageed, A. B., and Kumar, M. V. Reduced response of prostate cancer cells to TRAIL is modulated by NFκB-mediated inhibition of caspases and Bid activation. Int. J. Oncol., 21: 111-117, 2002.
38. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 104: 155-162, 1999.
39. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A., Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., and Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med., 7: 383-3851 2001.